Top 20 Promising Biotechs in Europe

Top 20 Promising Biotechs in Europe

European clinical research and biological drug development is experiencing a pivotal shift. Regulatory harmonisation initiatives across the continent have set out to reduce administrative friction and create a unified stage for medical breakthroughs. As capital flows into high-impact science, European biotechs are moving past structural barriers to deliver next-generation modalities.

Rather than listing established industry giants, this article explores 20 of the most promising European biotech ventures advancing through their clinical pipelines as of August 2026. These companies have been selected for their combination of scientific differentiation, translational or clinical progress, financing momentum, strategic partnerships and potential to influence the future direction of European biotechnology.

This list spans across companies at different stages of development, from newly launched preclinical ventures to publicly traded biopharma approaching pivotal clinical milestones.

Nuclidium (Basel, Switzerland/ Munich, Germany)

Nuclidium is a clinical-stage biotechnology company pioneering next-generation copper-based radiopharmaceuticals for cancer diagnosis and treatment. Its proprietary CuTrace platform pairs Copper-61 for diagnostic imaging with Copper-67 for therapy, linked to tumour-targeting molecules, enabling a ‘true theranostic’ approach designed to move directly from diagnosis to treatment using the same targeting chemistry.

The company's lead programmes, NU101 in metastatic castration-resistant prostate cancer and NU201 in metastatic breast cancer, are advancing through early-stage clinical trials, building on Phase I/II diagnostic data presented at nuclear medicine conferences including SNMMI and EANM. In May 2026, Nuclidium closed an oversubscribed Series B extension of €28.4M, bringing its total Series B financing to approximately €115M. The financing is supporting the initiation of Phase I/IIa therapeutic studies for NU101 and NU201, alongside continued buildout of the company's global manufacturing network for copper-based radiopharmaceuticals.

Adcytherix (Marseille, France)

Founded by the team behind Emergence Therapeutics, Adcytherix is a biopharmaceutical venture focused on next-generation ADCs for high-unmet-need solid tumours. The company utilizes its proprietary ADCX Engine to pair approved cancer therapeutics as novel payloads with custom-engineered linkers.

Adcytherix's lead program, ADCX-020, officially entered the clinic in March 2026, dosing its first patient in a Phase I open-label trial for patients with advanced solid tumours. Following a €105M Series A round in October 2025, Adcytherix continues to rapidly scale its broader preclinical pipeline.

Vandria (Lausanne, Switzerland)

Vandria is a clinical-stage biotechnology company developing small-molecule therapeutics intended to address diseases associated with mitochondrial dysfunction. Its approach is based on mitophagy, the cellular process through which damaged or dysfunctional mitochondria are selectively removed.

The company's lead programme, VNA-318, is an oral, brain-penetrant small molecule being developed initially for Alzheimer's disease. In July 2026, Vandria presented additional Phase I data at the Alzheimer's Association International Conference in London. The multiple-ascending-dose study provided evidence of pharmacodynamic activity in humans and supported the translation of VNA-318's proposed mechanism of action from preclinical models into clinical development. The findings provide a basis for further investigation of VNA-318 in neurodegenerative disease, although the programme remains at an early clinical stage and efficacy in patients has yet to be established.

Seamless Therapeutics (Dresden, Germany)

Seamless Therapeutics is pioneering the development of programmable recombinases to achieve precise, large-scale gene editing independent of cellular DNA repair mechanisms.

Its platform allows site-specific enzymatic insertion, inversion, or excision of large target sequences to correct complex genetic variants. In January 2026, Seamless entered into a strategic global collaboration with Eli Lilly and Company valued at over $1.12B in upfront and milestone payments. The collaboration focuses on programming recombinases to address defined genetic hearing loss indications, alongside Seamless’ internal rare disease pipeline.

Asgard Therapeutics (Lund, Sweden)

Asgard Therapeutics is developing an experimental cancer immunotherapy approach based on direct in-vivo cell reprogramming. Its technology is designed to convert tumour cells within the tumour microenvironment into conventional dendritic cells type 1 (cDC1), which can then help initiate an immune response against the tumour.

The company's lead programme, AT-108, uses a replication-deficient adenoviral vector carrying a proprietary combination of reprogramming factors. In 2026, Asgard presented new preclinical data showing systemic, dose-dependent anti-tumour activity in animal models, building on earlier studies in which AT-108 produced tumour regressions and evidence of immune memory. The company is now working to advance the programme toward clinical development. However, AT-108 remains a preclinical candidate, and the reported anti-tumour effects have not yet been demonstrated in human clinical trials.

Draig Therapeutics (Cardiff, United Kingdom)

Draig Therapeutics is a clinical-stage neuropsychiatry biotech targeting central nervous system disorders through selective small-molecule modulators of core neurotransmission pathways.

Its lead clinical asset, DT-101, is a novel compound that completed Phase I safety trials and moved into Phase II testing for major depressive disorder. Draig is also advancing selective GABAA receptor modulators for broader psychiatric conditions. To fund Phase II clinical readouts and platform growth, Draig raised a $65M Series B round in July 2026.

Bioptimus (Paris, France)

Bioptimus is developing foundation models for biology designed to analyse and integrate complex biological information across multiple scales and data types. Its M-Optimus model is intended to learn representations of biological systems from multimodal datasets, with potential applications across research, drug discovery and precision medicine.

In March 2026, Bioptimus launched STELA, a spatial biology initiative being developed with partners including 10x Genomics and Broad Clinical Labs, with the ambition of linking spatial and clinical data from up to 100,000 patient specimens. In August 2026, Bioptimus announced a partnership with Cancer Research Horizons giving it access to S:CORT, a multimodal colorectal cancer dataset containing more than 1,750 patient profiles. The data will be used to train and evaluate Bioptimus' AI foundation model, adding clinically linked cancer data to the company's growing biological datasets.

NanoPhoria Bioscience (Milan, Italy)

NanoPhoria is developing non-viral, inorganic nanoparticle drug delivery systems to deliver targeted therapies directly to heart tissue via simple dry powder inhalation.

The company’s primary focus is NP-MP1, an inhalable peptide therapeutic designed to restore functional performance in heart failure with reduced ejection fraction (HFrEF).

Building on positive preclinical pig model data published in the Journal of the American College of Cardiology, NanoPhoria completed an €83.5M Series A financing round with an additional investment from the European Innovation Council in late 2025 to bring its lead program into clinical development.

Orbis Medicines (Copenhagen, Denmark)

Orbis Medicines is engineering a new class of oral macrocycles, termed nCycles, designed to provide oral alternatives to injectable biological drugs. Macrocycles historically proved difficult to formulate for oral administration, but Orbis utilizes its high-throughput nGen platform to systematically optimize bio-availability.

The company closed a €90M Series A funding round led by New Enterprise Associates with participation from Eli Lilly. Orbis is deploying this funding to advance its preclinical nCycle pipeline against validated targets in immunology and metabolic disease.

Revier Therapeutics (Heidelberg, Germany)

Revier Therapeutics is a newly launched biotechnology company developing selective class IIa histone deacetylase (HDAC) inhibitors for cardiovascular and cardiometabolic diseases. Its approach is intended to selectively modulate disease-associated HDAC activity while avoiding the broader effects associated with less selective HDAC inhibition.

Revier emerged from stealth in August 2026 with a €6 million seed financing, led by KHAN Technology Transfer Fund II with participation from High-Tech Gründerfonds and other investors. The company's initial pipeline is focused on heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD). As a newly launched company, its programmes remain at the preclinical stage, making its scientific platform and ability to translate the approach into effective therapies the key areas to watch.

DISCO Pharmaceuticals (Cologne, Germany / Schlieren, Switzerland)

DISCO Pharmaceuticals is developing an approach to oncology drug discovery based on systematic analysis of the cancer cell surfaceome, the collection of proteins expressed on the surface of cells. By comparing surface protein expression across tumour and healthy tissue, the company aims to identify combinations of targets that could be exploited for more selective cancer therapies.

DISCO has built its discovery platform around high-resolution mapping of tumour surface proteins and is using the resulting data to identify targets for modalities including antibody-drug conjugates and T-cell engagers. The company secured €36M in financing in 2025, with proceeds supporting development of its oncology pipeline, including programmes in small-cell lung cancer (SCLC) and microsatellite-stable colorectal cancer. Its work includes mapping the SCLC surfaceome to support the identification and development of new therapeutic targets, although the resulting programmes remain in the preclinical and IND-enabling stages.

Aerska (Dublin, Ireland)

Aerska is an emerging biotech focused on building targeted delivery architectures for therapies directed at the central nervous system. The company seeks to overcome blood-brain barrier restrictions to deliver therapeutic payloads directly to affected neurological tissue.

Having launched out of stealth in late 2025, Aerska closed a $39M Series A funding round in February 2026, bringing its total financing to $60M. The funding accelerates the transition of its internal drug delivery platform and neurodegenerative disease toward first-in-human studies.

Noema Pharma (Basel, Switzerland)

Noema Pharma is a clinical-stage biotechnology company developing small-molecule treatments for neurological and neuropsychiatric disorders where significant unmet medical needs remain. They have assembled a pipeline of selective compounds that act on validated biological targets implicated in CNS disease.

Noema Pharma’s portfolio includes basimglurant (NOE-101), an mGluR5 negative allosteric modulator being investigated in neurological conditions including trigeminal neuralgia and seizures associated with tuberous sclerosis complex, and gemlapodect (NOE-105), a PDE10A inhibitor being evaluated in Tourette syndrome. Noema has raised substantial private financing to advance its clinical portfolio, including a CHF130M Series B financing announced in 2024. The company's programmes are at different stages of clinical development, making clinical efficacy and regulatory progress the key milestones to watch as the pipeline advances.

Myricx Bio (London, United Kingdom)

Myricx Bio is a biotechnology company developing antibody-drug conjugates (ADCs) using N-myristoyltransferase inhibitors (NMTi) as a novel payload class. Myricx Bio argues that NMT inhibition provides a mechanism distinct from more established ADC payloads such as topoisomerase I and tubulin inhibitors, potentially offering another way to address tumour resistance.

Myricx has developed preclinical ADC programmes against targets including B7-H3 and HER2. In July 2026, Novartis announced an agreement to acquire Myricx Bio for $1.1B and up to $1.5B including potential milestone payments, subject to customary closing conditions. The transaction highlights investor and pharmaceutical interest in Myricx's NMTi-ADC technology, although the company's therapeutic programmes remain at the preclinical stage.

Windward Bio (Basel, Switzerland)

Windward Bio is a clinical-stage biotechnology company developing ultra long-acting monoclonal antibodies for serious immunological diseases, with an initial focus on respiratory and dermatological conditions. Their strategy centers on extending dosing intervals for validated biological targets, aiming to differentiate its therapies through reduced treatment burden alongside best-in-disease efficacy potential.

The company's lead programme, WIN378, is an ultra long-acting anti-TSLP antibody designed to enable twice-yearly dosing in asthma and COPD, currently advancing through the Phase II/III POLARIS study with initial readouts expected in the second half of 2026. In May 2026, Windward Bio announced an upsized $165M crossover financing led by OrbiMed, with participation from new investors including RA Capital Management, Janus Henderson Investors and Sanofi Ventures, alongside existing backers such as Novo Holdings and Blue Owl Healthcare Opportunities. The round brought Windward Bio’s cumulative financing to more than $365M within its first 18 months of operation.

CarboCode (Constance, Germany/ Cantanhede, Portugal)

CarboCode is a biotechnology company developing scalable production methods for human-identical sphingolipids, including glycosphingolipids and gangliosides. These complex lipids occur naturally in human tissues and play roles in areas including cell signalling, membrane biology and nervous-system development, but can be difficult and expensive to obtain at commercial scale.

They combine biotechnology approaches including fermentation, biocatalysis and metabolic engineering to produce specialised lipids for applications such as infant nutrition, skincare and wellness, with potential applications in broader health and therapeutic markets. The company raised €15M in Series C financing in 2024, led by Iberis Capital, to support the development and scaling of its production platform. Unlike most of the therapeutics-focused companies on this list, CarboCode's near-term opportunity is primarily in biomanufacturing and health-related ingredients rather than clinical drug development.

Phagos (Paris, France)

Phagos is a biotechnology company developing bacteriophage-based approaches to antimicrobial resistance. Its platform uses naturally occurring viruses that selectively infect bacteria, with the aim of controlling pathogenic organisms while reducing the broad microbiome disruption associated with conventional antibiotics.

Their initial focus was on animal health, where antibiotic resistance and restrictions on antibiotic use create a significant need for alternative approaches. Phagos combines phage biology with computational technologies to identify and develop targeted antibacterial treatments. Its technology has progressed beyond laboratory research into animal-health applications, including poultry, cattle, swine and aquaculture. Phagos’ development work illustrates how phage-based therapeutics could provide more targeted alternatives to conventional antibiotics, although its principal commercial focus to date has been animal rather than human medicine.

Synaptiq Therapeutics (Reykjavik, Iceland)

Synaptiq Therapeutics is a newly established clinical-stage biotechnology company focused on developing treatments for rare neurological and neuropsychiatric disorders. They were launched in July 2026 following the acquisition of Nobias Therapeutics' clinical-stage programme NB-001, which has been renamed SYN-001.

SYN-001 is being developed for neuropsychiatric symptoms associated with 22q11.2 deletion syndrome (22q11DS) and has received FDA orphan-drug and rare pediatric disease designations. Synaptiq Therapeutics plans to advance the programme into a Phase IIb clinical trial. The company's launch brings together the existing clinical development programme with new investors and management, making it an unusually early but potentially significant addition to Europe's rare-disease biotechnology landscape.

Immitra Bio (Plan-les-Ouates, Switzerland)

Immitra Bio is an early-stage biotechnology company developing in-vivo gene-editing therapies with the aim of creating scalable alternatives to complex ex-vivo cell and gene therapies. The company's approach combines gene-editing technology with computational target discovery to identify opportunities where a genetic intervention could potentially produce a durable therapeutic effect from a single treatment.

Its lead programme, IB-003, is being developed as a potential one-time treatmen for an inherited anaemia and remains in preclinical development. In July 2026, Immitra announced a CHF2.4M pre-seed financing, led by Backbone Ventures and co-led by OCCIDENT. The proceeds are being used to fund preclinical proof-of-concept studies for IB-003, validate the company's platform and expand its pipeline.

Immatics (Tübingen, Germany)

Immatics is a clinical-stage biopharmaceutical company developing T-cell receptor (TCR)-based immunotherapies for solid tumours. Its XPRESIDENT platform is designed to identify tumour-associated targets, including peptides presented at low abundance on cancer cells, which can then be targeted through engineered T-cell therapies and TCR bispecific molecules.

The company's most advanced programme is Anzu-cel (IMA203), an autologous TCR-T cell therapy targeting the cancer antigen PRAME. Immatics is developing IMA203 across several solid-tumour indications while also advancing a broader PRAME-focused pipeline that includes TCR bispecific programmes. On 25 August 2026, Immatics announced a $150M underwritten offering of ordinary shares and pre-funded warrants, with the transaction expected to close on 26 August subject to customary conditions. The financing is intended to support the company's clinical development and broader PRAME franchise.

---

European biotech in 2026 is defined by a shift toward precision, novel delivery, and computational integration. Across modalities ranging from targeted ADCs and programmable recombinases to inhaled cardiotronics and AI biology platforms, these 20 biotechs demonstrate the depth and clinical execution driving the region's life sciences ecosystem forward.

References:

• European Biotechnology Magazine (Spring 2026 issue; released March 2026)

• BioSpace Press Releases & Corporate Announcements (November 2025 to August 2026)

• GlobeNewswire & BusinessWire Biotech Publications (January 2026 to August 2026)

• Pharmaceutical Technology & BioPharma Dive Financial Coverage (July 2026 to August 2026)

• Novo Holdings & Investor Portfolio Disclosures (July 2026)

---

About the Author

Rhys Wallett joined The PBC Group in October 2025 as a Conference Producer, where he researches and produces life sciences meetings for clinical-stage biopharma organisations.

In his role, Rhys develops targeted conference programs that bring together key stakeholders across the clinical research ecosystem, from CROs and pharmaceutical sponsors to biotech innovators and regulatory experts. His work focuses on identifying emerging trends in clinical development and translating complex industry challenges into actionable conference content that drives meaningful dialogue and collaboration within the life sciences community.